

TELEPHONE: 512/536-74-5201  
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER  
PARTNER

INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

RECEIVED


JUN 08 2001

TECH CENTER 1600/2900

FILE: UTSD:596US

1615#18  
6-13-01

June 4, 2001

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below.	
June 4, 2001 Date	 Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: *SN 09/460,292 "COMPOSITIONS AND METHODS OF MODULATING  
CHOLESTEROL METABOLISM" – David J. Mangelsdorf et al. (UTSMC/DAL:596)*

Commissioner:

Please find enclosed:

1. Communication;
2. Declaration of David Mangelsdorf Under 37 C.F.R. §1.132.;
3. Declaration Under 37 C.F.R. §1.48(a); and
4. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.


Commissioner for Patents

June 4, 2001

Page 2

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10017652/SLH.

Respectfully submitted,



Steven L. Highlander

Reg. No. 37,642

SLH/cpj

Encl.:

bcc: BethLynn Maxwell, Ph.D. (w/o encl.)  
Ray Wheatley, M.S. (w/encl.)  
David J. Mangelsdorf, Ph.D.(w/encl.)  
John M. Diestchy, M.D. (w/encl.)  
Stephen D. Turley, Ph.D. (w/encl.)  
Sanford J. Madigan, Ph.D.(w/encl.)  
David L. Parker, Esq. (w/o encl.)



RECEIVED

JUN 0 8 2001

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

David J. MANGELSDORF *et al.*

Serial No.: 09/460,292

Filed: December 10, 1999

For: COMPOSITIONS AND METHODS OF  
MODULATING CHOLESTEROL  
METABOLISM

Group Art Unit: 1615


Examiner: J. Woitach

Atty. Dkt. No.: UTSD:596/SLH

**CERTIFICATE OF MAILING**  
37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

June 4, 2001  
Date

  
Steven L. Highlander

COMMUNICATION


Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants hereby submit signed copies of declarations under 37 C.F.R. §1.132 and 37 C.F.R. §1.48(a), previously submitted in an unsigned form with the response filed on May 7, 2001. No fees are believed due in connection with this filing; however, should any fees be due, applicants authorizes the Commissioner to debit Fulbright & Jaworski Deposit Acct. NO. 55-1212/10017652/SLH. Please date stamp and return the enclosed postcard as proof of receipt.

Applicants again respectfully submit that all claims are in condition for allowance, and an early indication to that effect is earnestly solicited. Should Examiner Woitach have any questions regarding this response, he is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI, L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, TX 78701  
512-536-3184

Date: June 4, 2001